XML 40 R20.htm IDEA: XBRL DOCUMENT v3.25.0.1
Stock Option And Stock Award Plans
 12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Stock Option And Stock Award Plans
As of December 31, 2024, the Company had one stock-based compensation plan that permits the grants of stock options, stock appreciation rights (“SARs”), stock, restricted stock, and stock unit awards. Awards available for grant totaled 725,154 shares at December 31, 2024. Stock options may be granted to purchase a specified number of shares of common stock at a price no lower than the fair market value on the date of grant and for a term not to exceed 10 years. Stock options exercisable totaled 2,327,655 and 3,019,333 shares at December 31, 2024 and 2023, respectively.
A summary of stock options outstanding at December 31, 2024, 2023 and 2022, and changes during those years, is presented below:
  Option Exercise Price/Share
  Number of
Options		RangeWeighted
Average
Outstanding at January 1, 20223,125,944 $10.75 to$22.49 $13.82 
Forfeited and expired(17,203)14.47 to19.64 15.33 
Outstanding at December 31, 2022
3,108,741 10.75 to22.49 13.81 
Forfeited and expired(89,408)13.78 to19.64 19.60 
Outstanding at December 31, 2023
3,019,333 10.75 to22.49 13.64 
Forfeited and expired(691,678)10.75 to22.49 14.15 
Outstanding at December 31, 20242,327,655 $10.75 to$16.37 $13.49 
No options were granted in 2024, 2023 or 2022.
The following table summarizes additional information about stock options outstanding and exercisable at December 31, 2024:
 Options Outstanding at December 31, 2024Options Exercisable at December 31, 2024
  Weighted AverageAggregate Intrinsic Value  Aggregate Intrinsic Value
Range of
Exercise Prices		SharesRemaining Contractual LifeExercise
Price		SharesWeighted Average Exercise Price
$10.75 to$16.37 2,327,655 1.3 years$13.49 $— 2,327,655 $13.49 $— 
There were no stock options exercised in 2024, 2023 or 2022. The grant-date fair value of stock option-based awards vested in 2023 and 2022 was $2.2 million and $5.4 million, respectively. As of December 31, 2024, there was no unrecognized compensation cost related to stock option-based awards.
Restricted stock grants ordinarily vest three years from the date of grant based upon continued employment. The fair value of restricted stock awards is estimated as of the grant date using the closing stock price on that date.
Stock unit awards vest upon the achievement of certain performance targets.
The following table summarizes additional information about unvested restricted stock awards and performance stock units awards outstanding at December 31, 2024, 2023 and 2022:
 Unvested Restricted Stock AwardsMaximum Unvested Restricted Stock Units Issuable Upon Satisfaction of Certain Performance Criteria
 Number
of Shares		Weighted Avg. Grant Date Fair Value/ShareGrant Date
Fair Value
(In thousands)		Number
of Shares		Weighted Avg. Grant Date Fair Value/ShareGrant Date
Fair Value
(In thousands)
Outstanding at January 1, 2022335,800 $16.30 $5,473 50,718 $17.63 $1,366 
Granted301,969 11.88 3,587 — — — 
Vested(144,317)15.10 (2,179)— — — 
Forfeited(18,474)14.94 (276)(50,718)17.63 (1,366)
Outstanding at December 31, 2022474,978 13.82 6,564 — — — 
Granted454,623 7.67 3,487 — — — 
Vested(167,077)11.29 (1,886)— — — 
Forfeited(26,445)11.60 (307)— — — 
Outstanding at December 31, 2023736,079 10.68 7,861 — — — 
Granted385,159 7.25 2,792 — — — 
Vested(261,941)11.94 (3,128)— — — 
Forfeited(87,181)8.51 (742)— — — 
Outstanding at December 31, 2024772,116 $8.79 $6,787 — $— $— 
As of December 31, 2024, the unrecognized compensation cost related to non-vested restricted stock awards was $3.4 million. This cost is expected to be recognized over the remaining weighted average period of 1.8 years.
There were no SARs granted in 2024, 2023 or 2022. SARs may be settled in cash upon exercise and therefore are classified as liabilities and included in accrued expenses in the consolidated balance sheet. The fair value of these liability awards is remeasured at each reporting period until the date of settlement. Increases and decreases in stock-based compensation expense are recognized over the vesting period, or immediately, for vested awards.
A summary of SARs outstanding at December 31, 2024, 2023 and 2022, and changes during those years, is presented below:
  Exercise Price/Share
  Number of
SARs		RangeWeighted
Average
Outstanding at January 1, 2022521,601 $10.75 to$16.37 $13.55 
Forfeited and expired(22,914)10.75 to16.37 14.83 
Outstanding at December 31, 2022498,687 10.75 to16.37 13.49 
Forfeited and expired(53,969)10.75 to16.37 12.78 
Outstanding at December 31, 2023444,718 10.75 to16.37 13.57 
Forfeited and expired(110,272)10.75 to16.37 13.85 
Outstanding at December 31, 2024334,446 $10.75 to$16.37 $13.48 
The grant-date fair value of SARs awards vested in 2022 was $0.5 million. The grant-date fair value of SARs awards vested in 2024 and 2023 was immaterial. As of December 31, 2024, there was no unrecognized compensation cost related to SARs